MCLEAN, VA — Mars, Incorporated has announced a pivotal leadership transition within its sprawling pet care ecosystem. Carlos Andres-Luna, a seasoned executive with a robust background in scaling purpose-driven businesses within the multinational conglomerate, has been named Global President for its Science & Diagnostics division.

Effective January 1, Andres-Luna assumes leadership of a vital sector that sits at the intersection of veterinary medicine, biotechnology, and data analytics. He will report directly to Marc Carena, President of Mars Petcare, succeeding Katie Devine, who departs following a successful tenure spearheading the division’s growth and strategic positioning.

The appointment comes at a time of rapid technological convergence in the animal health sector. As pet ownership surges globally and pet parents demand human-grade healthcare for their companion animals, Mars Petcare is leaning heavily into science-led interventions. Andres-Luna’s mandate will be to steer this technological evolution, unifying a diverse portfolio of advanced diagnostics, pharmaceuticals, genomics, and foundational veterinary research.


Main Facts

The leadership transition places a seasoned internal candidate at the helm of one of the pet care industry’s most technologically integrated divisions.

  • The Appointee: Carlos Andres-Luna, formerly Regional President for Rapid Growth Markets at Mars’ Royal Canin division. He officially steps into the role on January 1.
  • Reporting Line: Andres-Luna will report directly to Marc Carena, Global President of Mars Petcare.
  • The Portfolio: The Science & Diagnostics division encompasses a sweeping range of advanced veterinary solutions, including:
    • Antech: Veterinary diagnostics featuring in-house diagnostic tools, reference laboratories, advanced imaging equipment, and integrated clinical software platforms.
    • Vetsource: A comprehensive pharmacy, nutrition home-delivery service, and clinical operations software provider.
    • Global Genomics: Industry-leading DNA testing brands, including Wisdom Panel and ANTAGENE.
    • The Waltham Petcare Science Institute: The foundational research arm of Mars, which has studied pet nutrition and health for over six decades.
  • Predecessor: Andres-Luna succeeds Katie Devine, who successfully expanded and structured the Science & Diagnostics unit during her tenure.

Chronology: The Making of a Global Executive

Carlos Andres-Luna’s path to the global presidency of Science & Diagnostics is marked by a steady ascension through top-tier financial, consulting, and consumer-goods institutions.

  • Pre-Mars Career: Before entering the consumer goods and pet care space, Andres-Luna developed a sharp analytical foundation in finance and management consulting. He began his career as an investment banker at J.P. Morgan Investment Bank, later transitioning to a strategy consultant at Bain & Company, where he honed his expertise in operational scaling and corporate restructuring.
  • 2009 — Joining Mars: Andres-Luna officially entered the Mars ecosystem, initially embedding himself within the Royal Canin brand. Over more than a decade and a half, he climbed the corporate ladder by taking on increasingly complex regional and functional challenges.
  • Mid-Tenure Leadership: Within Royal Canin, Andres-Luna served in pivotal capacities, including Chief Customer Officer and General Manager of European Key Accounts. In these roles, he forged deep, strategic partnerships with major veterinary hospital groups across Europe, gaining granular insight into the operational needs and clinical pain points of veterinary professionals.
  • Recent Role: Most recently, he served as Regional President for Rapid Growth Markets at Royal Canin. In this capacity, he worked extensively alongside breeders and veterinarians to leverage feline and canine nutrition as a mechanism for preventative health care, proving his ability to scale market share in diverse economic landscapes.
  • January 1 — The New Chapter: Andres-Luna assumes his role as Global President of Science & Diagnostics, tasked with bringing his extensive commercial acumen and strategic vision to the cutting-edge science division.

Supporting Data and Portfolio Scope

To understand the magnitude of Andres-Luna’s new role, one must examine the vast structural architecture of the Science & Diagnostics unit. Mars Petcare is not merely a consumer products company; it operates one of the most comprehensive veterinary health ecosystems in the world.

1. Veterinary Diagnostics and Infrastructure (Antech)

Antech Diagnostics provides the clinical backbone for thousands of independent and corporate veterinary practices worldwide. The portfolio includes state-of-the-art reference laboratories that process millions of diagnostic tests annually, alongside in-house point-of-care diagnostic hardware. Furthermore, Antech provides sophisticated imaging equipment—such as digital radiography and ultrasound systems—paired with integrated software platforms designed to streamline clinic workflows and reduce administrative friction for overworked veterinary teams.

2. Pharmacy, Nutrition, and Practice Management (Vetsource)

Vetsource bridges the gap between veterinary clinics, pet parents, and manufacturers. By powering home-delivery infrastructure for both pharmaceutical prescriptions and specialized therapeutic nutrition, Vetsource enables clinics to capture revenue that might otherwise be lost to online third-party retailers. Additionally, its data and software services supply clinical teams with actionable insights to optimize practice management, inventory control, and client communication.

3. Advanced Genomics (Wisdom Panel & ANTAGENE)

In the realm of preventative medicine, genomics is playing an increasingly dominant role. Through brands like Wisdom Panel and ANTAGENE, Mars operates a global genomics business that delivers consumer and clinical DNA testing. These tests screen for breed identification, ancestry, and hundreds of genetic health conditions, empowering veterinarians to practice proactive, personalized medicine long before clinical symptoms manifest.

4. Foundational Research (The Waltham Petcare Science Institute)

Beyond commercial diagnostics and products, Andres-Luna will oversee the scientific agenda executed at the Waltham Petcare Science Institute. For over 60 years, Waltham has served as a global scientific authority in pet nutrition, biomarker research, and microbiome analysis. The insights generated at Waltham directly inform the product formulations of Royal Canin, the diagnostic markers utilized by Antech, and the broader veterinary community’s understanding of feline and canine longevity.


Official Responses and Executive Vision

The leadership announcement drew enthusiastic responses from both executive leadership and the incoming president, underscoring Mars’ deeply embedded corporate ethos of "A BETTER WORLD FOR PETS."

Marc Carena, Global President of Mars Petcare, expressed absolute confidence in the appointment, highlighting Andres-Luna’s history of purpose-driven leadership:

"I’m excited to welcome Carlos to the team. He has built a fantastic career across Mars, driving purpose-led growth. We are confident he will make a significant contribution to our Science & Diagnostics business, driving positive health outcomes for pets and delivering on our purpose: A BETTER WORLD FOR PETS."

Carena’s remarks emphasize that despite the heavy emphasis on biotechnology, software, and laboratory infrastructure, the ultimate metric of success for Mars remains qualitative: improving and prolonging the lives of cats and dogs.

For his part, Carlos Andres-Luna framed his new assignment not merely as a corporate promotion, but as an opportunity to empower the professionals on the front lines of animal care:

"Pets make our lives infinitely better, and our talented team of researchers, scientists, veterinarians, and engineers work to advance science and diagnostics to make sure every pet gets the care they deserve. I’m delighted to join them, and to work together to deliver even greater impact."

Andres-Luna’s background in building collaborative networks between manufacturers, breeders, and veterinarians positions him uniquely to bridge the gap between laboratory bench science and daily clinical application.


Implications for the Pet Care Industry

The appointment of Carlos Andres-Luna signals several broader strategic trajectories for Mars, Incorporated and the global animal health sector at large.

1. Accelerated Convergence of Nutrition, Diagnostics, and Therapeutics

For decades, pet care was heavily segmented: pet food brands sold nutrition, veterinary clinics practiced medicine, and diagnostic laboratories operated independently. Under leaders like Andres-Luna, Mars has actively pursued an ecosystem model. By housing reference laboratories (Antech), home-delivery pharmacy (Vetsource), genetic screening (Wisdom Panel), clinical research (Waltham), and specialized therapeutic nutrition (Royal Canin) under one corporate umbrella, Mars is uniquely positioned to offer an unbroken continuum of care. Andres-Luna’s deep familiarity with the veterinary channel gained during his tenure at Royal Canin will be instrumental in weaving these disparate threads into a seamless experience for veterinary practitioners.

2. Addressing the Veterinary Burnout Crisis

The global veterinary industry faces an acute labor shortage and burnout crisis, driven by heavy administrative burdens, rising client expectations, and high patient volumes. The Science & Diagnostics division plays a critical role in mitigating these pressures through workflow-optimizing software, streamlined reference lab integration, and home-delivery pharmacy solutions that unburden clinic staff. Andres-Luna’s operational experience will likely prioritize scaling these technological efficiencies, providing much-needed operational relief to clinical teams.

3. The Shift Toward Predictive and Personalized Pet Medicine

Just as human medicine is transitioning from reactive treatment to proactive prevention, veterinary medicine is following suit. The integration of genetic testing (Wisdom Panel) with advanced diagnostic imaging and continuous clinical data analytics allows veterinarians to predict hereditary conditions and catch progressive diseases (such as chronic kidney disease or osteoarthritis) in their earliest, most treatable stages. Under Andres-Luna’s leadership, the Science & Diagnostics division is expected to double down on biomarker discovery and preventative diagnostic tools, ensuring that Mars remains at the vanguard of the pet health revolution.

As Carlos Andres-Luna steps into his new office on January 1, he inherits a business unit that is both a commercial powerhouse and a scientific pioneer. With the pet care market continuing its historic expansion, the decisions made under his leadership will profoundly shape how veterinary medicine is practiced, and how millions of pets experience health and longevity, for years to come.